Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Whether the anti-gp210 antibody can be used as a biomarker in patients with primary biliary cholangitis (PBC) remains controversial.
Aims: We aimed to investigate the association between anti-gp210 antibodies and prognosis in ursodeoxycholic acid (UDCA)-treated PBC patients.
Methods: We conducted a retrospective cohort study of 180 UDCA-treated PBC patients to assess the prognostic value of anti-gp210 antibodies using the Kaplan-Meier method and Cox proportional hazard regression analysis.
Results: Of the patients included in our analysis, 50 (27.8%) were anti-gp210 positive, and 130 (72.2%) were anti-gp210 negative. The incidence of liver-related death or transplantation was more common in the anti-gp210 + group (22.0 vs. 9.2%, P=0.022). The five-year transplant-free survival rates of anti-gp210-positive patients vs. anti-gp210-negative patients were 77.0% and 90.3%, respectively. We found that the probability of transplant-free survival was significantly lower in the anti-gp210-positive patients than in the anti-gp210-negative patients (log-rank P=0.004). After adjusting for potential confounders using multivariable Cox regression model, positivity for anti-gp210 antibody (hazard ratio: 4.619, 95% confidence interval: 1.895-11.261, P=0.001) was found to be independently associated with an increase in liver-related mortality or transplantation.
Conclusion: In this cohort of UDCA-treated PBC patients, positivity for anti-gp210 antibody was independently associated with a higher risk of liver-related death or transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2021.10.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis].
Zhonghua Gan Zang Bing Za Zhi
July 2025
Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin 300052, China.
To explore the clinical characteristics and identification of the independent risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis (PBC). A retrospective cohort study was performed. A total of 323 cases with PBC diagnosed in Tianjin Medical University General Hospital from January 2013 to June 2023 (125 patients with anti-gp210 antibody-positive and 198 patients with anti-gp210 antibody-negative) were included.
View Article and Find Full Text PDFAnti-GP210 Antibodies as a Primary Driver of Pruritus: A Hypothetical Two-Hit Model Beyond PBC.
Int J Rheum Dis
August 2025
Facultad de Medicina Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.
Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease. Despite established first-line therapy with ursodeoxycholic acid (UDCA), many patients do not achieve biochemical remission. Data on the characteristics of PBC in Poland remain limited.
View Article and Find Full Text PDFAnti-RPL30 as a novel biomarker for enhanced diagnosis of autoantibody-negative primary biliary cholangitis.
World J Gastroenterol
May 2025
State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
Background: The diagnosis of primary biliary cholangitis (PBC) remains challenging, particularly in cases where anti-mitochondrial antibody (AMA), anti-mitochondrial E2 subunit antibody (AMA-M2), anti-glycoprotein 210 (anti-gp210), and anti-speckled protein 100 (anti-Sp100) are all negative. In such instances, the condition is often confirmed through a liver needle biopsy.
Aim: To identify additional plasma biomarkers for non-invasive diagnostic methods of PBC.
Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.
J Clin Transl Hepatol
March 2025
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background And Aims: The diagnostic value of primary biliary cholangitis (PBC)-specific antibodies in patients with elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels, and other identifiable causes, was unclear. Our study aimed to determine whether etiological treatments in PBC-specific antibody-positive patients could improve liver biochemical tests, thereby distinguishing them from individuals with PBC.
Methods: We enrolled patients who were positive for PBC-specific antibodies and elevated ALP and/or GGT levels but with other identifiable etiologies.